Improvement and New Aspects of HCV Testing for Clinical Management

Mehmet ÖZDEMİR, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Konya, Türkiye)
Mustafa ALTINDİŞ (Sakarya Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Sakarya, Türkiye)
Viral Hepatitis Journal
0 0
Yıl: 2013 Cilt: 19 Sayı: 3 Sayfa Aralığı: 93 - 98 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Improvement and New Aspects of HCV Testing for Clinical Management

Öz:
Son zamanlarda Hepatit C enfeksiyonu olan hastaların tedavisi için oral yolla verilenonaylı ilaçların artması ve bu enfeksiyon için hasta başı testlerin toplum taramasındakullanılması, Hepatit C enfekte bireylerin tanı konmasında genişletici bir etkiyaratmıştır. Buna rağmen HCV enfeksiyonunun yaygın tanısı, anti-HCV antikor veyaçekirdek (kor) antijen testine ve teyit edici test olarak nükleik asit saptanmasınadayanmaktadır. Tedavi mevcut enfeksiyonu olan hastaları hedeflemekte iken,enfeksiyonun kanıtı için testler, HCV viremisini tespite odaklanmaktadır. HCV RNAnükleik asit testi ile ilgili karmaşıklığı ve maliyetleri en aza indirmek ve HCV korantijen testlerinin geliştirilmesi ve validasyonunun gerçekleşmesi, HCV-viremisi olanbireylerin tanımlanmasını hızlandıracaktır. Validasyon ve maliyet-etkinlik çalışmaları,HCV viremisini en iyi şekilde tespit etmek için ve HCV RNA tespit edilmeyen kişilerdekiyalancı antikor pozitifliği ile geçirilmiş HCV arasındaki ayrımı yapmak amacıylasürekli yürütülen uygulamalardır. HCV enfeksiyonu yönetimindeki iki önemli nokta;yeni enfeksiyonu tanımlamak ve ilaca dirençli HCV sürveyansını sürdürmektir. Bu ikinoktanın çözümlenmesi sürecindeki olumlu gelişmeler, HCVnin ortadan kaldırılmasıiçin umutları güçlendirecektir.
Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Kliniğin Yönetiminde Hepatit C Testlerinde Gelişmeler ve Yeni Yaklaşımlar

Öz:
Recent increase in approvals of orally delivered pharmaceuticals for the treatmentof patients with infection by Hepatitis C virus and of a point-of-care assay forcommunity screening of HCV infection have generated impetus to widen theidentification of HCV-infected individuals. Diagnosis of HCV infection is, however,still based on the detection of anti-HCV antibody, or core antigen test and nucleicacid testing as supplementary test. As treatment is intended for individuals withcurrent infection, testing for evidence of infection would need to centre on thedetection of HCV viremia. Minimizing the complexity and costs associated with HCVRNA testing and speeding the development and validation of HCV Core antigenassays expedite the identification of HCV-viremic individuals. Validation and cost- effectiveness studies are ongoing to inform the best practices for detecting HCVviremia and for distinguishing between resolved HCV infection and false positivityfor HCV antibody in persons in whom HCV RNA is not detected. Diagnosing recentHCV infection and engagement in surveillance of drug-resistant HCV are twoimportant points in management of HCV infection. Successful implementation ofthese measures brightens prospects for the eventual elimination of HCV.
Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Tang H, Grise H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci, 2009;117: 49–65.
  • 2. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962–73.
  • 3. Lauer MG, Walker BD. N Engl J Med. 2001; 345:41-52.
  • 4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2014; 60 : 392–420.
  • 5. Yang R, Guan W, Wang Q, Liu Y, Wei L. Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays. Clin Chim Acta. 2013 ;426C:95-101. doi: 10.1016/j.cca.2013.09.010. [Epub ahead of print]
  • 6. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012; 55 (Suppl 1): S43-8.
  • 7. Kesli R, Ozdemir M, Kurtoglu MG, Baykan M, Baysal B. Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme- linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res. 2009; 37(5): 1420-9.
  • 8. CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945- 1965. MMWR 2012; 61: 4.
  • 9. CDC. Viral hepatitis surveillance, United States, 2009–2011. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at http://www.cdc.gov/hepatitis/ statistics/2010surveillance/index.htm.
  • 10. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 19.
  • 11. CDC. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR 2003; 52: 3.
  • 12. CDC. Vital signs: evaluation of hepatitis C virus infection testing and reporting—eight U.S. sites, 2005–2011. MMWR 2013; 62: 18.
  • 13 CDC.Testing for HCV infection:an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013; 62(18): 362-5.
  • 14. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 558-66.
  • 15. Corstjens PL, Abrams WR, Malamud D. Detecting viruses by using salivary diagnostics. J Am Dent Assoc. 2012; 143(10): 12S-8S.
  • 16. Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 2013; 106: 153-63.
  • 17. Montesinos I, Desomberg L, Delforge LM. Comparison of Two HCV Confirmatory Tests: MP Diagnostics HCV Blot 3.0 and CHIRON RIBA HCV 3.0. J Immunol Tech Infect Dis 2013; 2:3.
  • 18. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J of Hepatol. 2011; 55(3): 692–701.
  • 19. Altındis M, Yoldas O, Bulut A, Demiral T, Demirtürk N. ‘‘IL28B polymorphisms associated with therapy response in turkish chronic hepatitis C patients’’. The 5th Eurasia Congress of Infectious Diseases, 15-18 May 2013,Tirana, Albania.
  • 20. Ruhwald M, Andersen ES, Christensen PB, Moessner BK, Weis N. IP-10 Can Be Measured in Dried Plasma Spots in Patients with Chronic Hepatitis C Infection. PLoS One. 2012; 7(9): e45181.
  • 21. Gale HB, Dufour DR, Qazi NN, Kan VL. Comparison of serial hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation. J Clin Microbiol. 2011; 49: 3036–9.
  • 22. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19: 449–64.
  • 23. Vermeersch P, Van Ranst M, Lagrou K. Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory. J Clin Virol. 2008;42:394–8.
  • 24. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49: 1335–74.
  • 25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55: 245–64.
  • 26. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44.
  • 26. Chevaliez S, Bouvier-Alias M, Brillet R, et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009; 4: e8209.
  • 28. Clark PJ, Thompson AJ. Host genomics and HCV treatment response. J Gastroenterol Hepatol. 2012; 27: 212–22.
  • 29. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012;142(6):1314-1323.e1. doi: 10.1053/j.gastro.2012.02.013
  • 30. Pawlotsky JM. Treatment failure and resistance with direct- acting antiviral drugs against hepatitis C virus. Hepatology. 2011; 53: 1742-51.
  • 31. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol. 2011; 54:S4.
  • 32. Zeuzem S, Barnard RJ, Howe JA, et al. Boceprevir resistance associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon-2b/ ribavirin. J Hepatol. 2011; 54: S4–S5.
  • 33. Chevaliez S, Rodriguez C, Pawlotsky JM. New Virologic Tools for Management of Chronic Hepatitis B and C. Gastroenterology. 2012; 142: 1303–13.
  • 34. Chevaliez S. New markers for diagnosis and management of chronic hepatitis C virus infection. Annals of Gastroenterology. 2013; 26: 98-99.
APA OZDEMIR M, ALTINDİŞ M (2013). Improvement and New Aspects of HCV Testing for Clinical Management. , 93 - 98.
Chicago OZDEMIR MEHMET,ALTINDİŞ Mustafa Improvement and New Aspects of HCV Testing for Clinical Management. (2013): 93 - 98.
MLA OZDEMIR MEHMET,ALTINDİŞ Mustafa Improvement and New Aspects of HCV Testing for Clinical Management. , 2013, ss.93 - 98.
AMA OZDEMIR M,ALTINDİŞ M Improvement and New Aspects of HCV Testing for Clinical Management. . 2013; 93 - 98.
Vancouver OZDEMIR M,ALTINDİŞ M Improvement and New Aspects of HCV Testing for Clinical Management. . 2013; 93 - 98.
IEEE OZDEMIR M,ALTINDİŞ M "Improvement and New Aspects of HCV Testing for Clinical Management." , ss.93 - 98, 2013.
ISNAD OZDEMIR, MEHMET - ALTINDİŞ, Mustafa. "Improvement and New Aspects of HCV Testing for Clinical Management". (2013), 93-98.
APA OZDEMIR M, ALTINDİŞ M (2013). Improvement and New Aspects of HCV Testing for Clinical Management. Viral Hepatitis Journal, 19(3), 93 - 98.
Chicago OZDEMIR MEHMET,ALTINDİŞ Mustafa Improvement and New Aspects of HCV Testing for Clinical Management. Viral Hepatitis Journal 19, no.3 (2013): 93 - 98.
MLA OZDEMIR MEHMET,ALTINDİŞ Mustafa Improvement and New Aspects of HCV Testing for Clinical Management. Viral Hepatitis Journal, vol.19, no.3, 2013, ss.93 - 98.
AMA OZDEMIR M,ALTINDİŞ M Improvement and New Aspects of HCV Testing for Clinical Management. Viral Hepatitis Journal. 2013; 19(3): 93 - 98.
Vancouver OZDEMIR M,ALTINDİŞ M Improvement and New Aspects of HCV Testing for Clinical Management. Viral Hepatitis Journal. 2013; 19(3): 93 - 98.
IEEE OZDEMIR M,ALTINDİŞ M "Improvement and New Aspects of HCV Testing for Clinical Management." Viral Hepatitis Journal, 19, ss.93 - 98, 2013.
ISNAD OZDEMIR, MEHMET - ALTINDİŞ, Mustafa. "Improvement and New Aspects of HCV Testing for Clinical Management". Viral Hepatitis Journal 19/3 (2013), 93-98.
Sayfa Oluşturulma Tarihi
13-05-2024 9:30

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları